Johns Hopkins University emerges as a central site in the renewed investigation of Psilocybin: not simply a laboratory producing clinical results, but an institution where research, guided experience, and difficult questions about evidence meet. Its work includes studies of cancer-related distress and smoking cessation, while the account connects Hopkins to a longer history of psychedelic research and to practices developed outside universities. That combination gives the institution a distinctive role: it helps bring a once-disrupted field back into formal medicine, yet its findings remain part of an inquiry that must distinguish encouraging signals from established treatment effects.

Research and institutional setting

The Hopkins studies belong to a broader revival of inquiry that resumed after sanctioned psychedelic therapy ended in the 1970s. The New York University cancer study and the sister study conducted in the lab of Roland Griffiths at Johns Hopkins University sought to examine whether psychedelic treatment could help people facing the end of life. The account places these projects among a small number of efforts to pick up a line of research that had been abandoned for decades. Other contemporary trials were asking whether Psilocybin might help with depression or addiction, extending the questions beyond the immediate circumstances of terminal illness.

The institution also appears in an earlier moment in the field’s history. A source passage notes that a previous experiment was replicated, roughly speaking, at Johns Hopkins in 2006. The brief reference does not specify the design or findings, but it locates Hopkins within the renewed return to research after the long interruption. Later, the university’s work would become part of a much more visible clinical conversation, with results reported in national news and presented to federal regulators.

The clinical work did not arise in isolation from the experience of guides and therapists. The book describes a continuing, if cautious, traffic between underground practitioners and university research: some experienced guides were recruited to train a new cohort for formal trials, and Hopkins is mentioned in a discussion of how researchers approached the role of guidance. The broader practice drew on accumulated knowledge about preparation, intention, the stages of a session, responding to frightening material, and post-session integration. This history helps explain why Hopkins’s research is described not as the administration of a drug alone, but as work conducted through structured human encounters.

Guidance during the psychedelic session

The importance of the guide is visible in the account of the Hopkins sessions. Their instructions emphasized meeting difficult imagery rather than turning away from it: participants were encouraged to approach what frightened them, remain present, and seek to understand what the experience might disclose. That approach stands in contrast to a model in which the session is treated as a passive reaction to a chemical. Within the narrative, the guide’s task is to help create conditions in which a challenging episode can be faced rather than simply endured.

Hopkins’s place in this history also intersects with the underground lineage of psychedelic therapy. Many later guides traced their professional ancestry to therapists and researchers active in the 1950s and 1960s, including Leo Zeff, Al Hubbard, Stanislav Grof, or Timothy Leary’s students. The later return of university research did not erase this informal transmission of practice. Rather, the account suggests that early research and underground experience both contributed to the knowledge available to the revived field. Hopkins therefore represents a formal research setting operating within a larger network of clinical memory and guidance, even as universities have reasons to be cautious about acknowledging that connection.

Cancer studies and a shift in ambition

In December 2016, the results of the Johns Hopkins and New York University Psilocybin cancer studies were published together in a special issue of the Journal of Psychopharmacology. A front-page report in the New York Times brought the findings to wide public attention. Nearly a dozen accompanying commentaries welcomed the results, including responses from two past presidents of the American Psychiatric Association. The publication and its reception marked a change in visibility: work that had been confined to a small research community was now being discussed by prominent figures in mental health and in the national press.

The studies’ next consequence came in early 2017, when Roland Griffiths and Stephen Ross brought their clinical results to the Food and Drug Administration, seeking approval for a larger phase 3 trial of Psilocybin for cancer patients. The regulators surprised the researchers by asking them to broaden the question. Rather than focus only on cancer-related distress, they proposed testing whether Psilocybin could address depression in the general population, a much larger public-health problem. They considered the results strong enough to warrant examining that possibility despite major research difficulties: participants and therapists can often tell whether the drug has been given, therapy and medication are combined, and the substance remains illegal. The episode made Hopkins’s work consequential beyond its original patient group, while leaving the proposed expansion as a question for further study rather than proof of a general treatment effect.

Smoking-cessation research

A second major Hopkins line of work concerned smoking. Matthew Johnson, a psychologist trained in behaviorist research, had worked on early Psilocybin studies at the university, guided several dozen sessions, and helped analyze data before beginning a study of his own in 2009. The pilot enrolled fifteen smokers who wanted to quit. Participants first received several sessions of cognitive behavioral therapy and then two or three Psilocybin doses. It was open-label, with no placebo group, so participants knew they were receiving the drug. They had to stop smoking before a session, and researchers measured carbon-monoxide levels at intervals to check their abstinence.

The results were striking but came from a small, nonrandomized study. Six months after the sessions, 80 percent of the volunteers had been confirmed abstinent; at one year, the reported proportion was 67 percent. The account notes that this remained better than the success rate of the best treatment then available, while also reporting that a larger randomized comparison with the nicotine patch was under way. The volunteers who underwent the most complete mystical experiences had the strongest outcomes. Charles Bessant, one of the participants, had remained abstinent for six years by the time he was described. His case gives the study a human measure, but it does not remove the limitations of the pilot’s size and design.

Promise and evidentiary limits

The Hopkins work is presented as promising without being treated as conclusive. Small early studies can make a new intervention look especially powerful: participants may be selected from those most likely to respond, researchers and therapists may favor a positive outcome, and intensive care from unusually dedicated staff can shape the experience. When there is no placebo or effective blinding, expectation is another possible influence. These cautions matter particularly for studies in which the treatment includes both a drug and a therapeutic relationship, because the contribution of each element is difficult to isolate.

The contrast with earlier research sharpens the point. In the Toronto replication of the Saskatchewan LSD trials for alcohol dependence, clinicians tried to isolate the drug by placing volunteers in neutral rooms, limiting interaction, and administering extensive questionnaires; some participants were restrained or blindfolded, and several had frightening experiences. The results did not match those obtained by Humphry Osmond and Abram Hoffer. The episode showed that rigorous controls and supportive conditions answer different questions: an austere design may test the drug apart from the therapeutic setting, while also removing conditions considered essential to the treatment. Hopkins’s guided studies belong to this continuing methodological debate. Their significance lies both in the outcomes that renewed interest and in the unresolved challenge of determining what produces them, for whom, and under what conditions.